Key Takeaways NVO reports amycretin drove notable weight loss versus placebo in type 2 diabetes patients.Subcutaneous and oral amycretin cut HbA1c levels by up to 1.8% and 1.5% by week 36, respectively.Both formulations were generally well tolerated, with phase III plans on amycretin set for 2026.Shares of Novo Nordisk (NVO) were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 diabetes.The ...

点击蓝字，关注我们 今日上午港股 1 . 维他奶国际(00345)微涨0.15% 。消息面上，维他奶国际昨日公布截至2025年9月30日止6个月中期 业绩，收入同比减少6%；毛利同比减少7%。收入减少6%主要由于中国内地业务受市况疲弱影响，表 现面临挑战。 6. 绿叶制药(02186)涨近2% 。消息面上，11月24日，绿叶制药发布公告，该集团自主研发的新一代5- 羟色胺2A型受体(5-HT2AR)反向激动剂和5-羟色胺2C型受体(5-HT2CR)拮抗剂LY03017已获得美国食 品药品监督管理局(FDA)许可开展临床试验。 7 . 恒瑞医药(01276)涨超5% 。消息面上，11月25日晚，恒瑞医药公告收到国家药品监督管理局核准签 发关于两项药物临床试验批准通知书。公告指出，HRS-8364片将于近期开展在晚期实体瘤中开展临 床试验。 8 . 美团-W(03690)早盘涨6% 。消息面上，阿里巴巴集团CFO徐宏在三季度财报会上透露，公司对淘 宝闪购的投入将在9月季度达到高点。 9 . 阿里巴巴-W(09988)盘中跌近2% 。消息面上，11月25日，阿里巴巴发布了截至2025年9月30日止季 度及六个月业绩 ...

Core Insights - Novo Nordisk announced clinical trial data for its new diabetes drug amycretin, demonstrating significant weight loss effects alongside blood sugar reduction [2] Group 1: Clinical Trial Results - The trial results indicate that the amycretin injection, administered once weekly, can help patients lose up to 14.5% of their body weight over 36 weeks [2] - The daily oral formulation of amycretin can achieve a weight loss of up to 10.1% [2] Group 2: Market Impact - This positive news led to a rise in Novo Nordisk's stock price in the US, recovering much of the losses incurred from the underperformance of its Ozempic oral version in two Alzheimer's clinical trials [2] Group 3: Strategic Importance - Amycretin is a key component of Novo Nordisk's new generation of drug combinations, integrating two weight loss mechanisms into a single molecule, aimed at enhancing the company's competitive position in the obesity treatment market [2]

诺和诺德公司公布的新一代糖尿病药物amycretin临床试验数据显示，该药物在降低血糖的同时实现显著减重效果，为这家 市值今年蒸发过半的丹麦制药商带来提振。 周二，诺和诺德发布的试验结果显示，amycretin注射剂每周给药一次，可在36周内帮助患者减轻最多14.5%的体重，而每 日口服制剂的减重幅度可达10.1%。 Shah补充道： 不过，诺和诺德试验中的患者体重更重，而体重较重的人群初期减重可能相对容易。 Shah认为： 在大型后期研究中，amycretin对血糖的影响小于礼来公司的药物，但包括副作用在内的详细数据将是关键。 据报道，Amycretin是诺和诺德新一代药物组合中的关键一环，该药物将两种减重机制整合到单一分子中。 消息推动诺和诺德的美股股价收涨超4.6%，收复昨日Ozempic药物实验失败带来的大部分跌幅。 华尔街见闻提及，周一诺和诺德宣布，公司的Ozempic口服版本在两项大型临床试验中未能减缓阿尔茨海默症进展。基于认 知评估结果，服用该药物的患者并未出现显著好转。 而针对此次amycretin的实验结果，彭博行业研究分析师Michael Shah表示，尽管因临床试验设计不同难以直接比较， ...

Key Points The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes. The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial for semaglutide in Alzheimer's. 10 stocks we like better than Novo Nordisk › Another day and another release of results from a clinical trial from Novo Nordisk (NYSE: NVO). However, this time it's positive news. Here's the lowdown. Novo Nordisk trial results The pharmaceutical company is best ...

周二，诺和诺德(NVO.US)股价逆市上涨，截至发稿，该股涨超2.9%，报46.3美元。消息面上，该公司 表示，其下一代减重与糖尿病候选药物amycretin在最新研究中展现显著疗效，不仅有效降低患者血糖， 还实现明显体重下降，为这家在减重市场竞争中承压的药企带来一线利好。 分析师Michael Shah表示，从减重效果看，amycretin的表现优于礼来(LLY.US)旗下的Zepbound以及次世 代口服药orforglipron，但由于试验设计不同，两者难以直接比较；此外，诺和诺德试验中的受试者整体 更重，而体重较高者在初期更容易出现较大幅度减重。 研究显示，患者每周注射一次amycretin，36周内体重平均下降幅度高达14.5%；若以口服方式、每日一 次服用，患者体重也平均下降10.1%。诺和诺德表示，这是该公司在下一代代谢类药物布局中的关键成 果。 ...

分析师Michael Shah表示，从减重效果看，amycretin的表现优于礼来(LLY.US)旗下的Zepbound以及次世 代口服药orforglipron，但由于试验设计不同，两者难以直接比较；此外，诺和诺德试验中的受试者整体 更重，而体重较高者在初期更容易出现较大幅度减重。 智通财经APP获悉，周二，诺和诺德(NVO.US)股价逆市上涨，截至发稿，该股涨超2.9%，报46.3美 元。消息面上，该公司表示，其下一代减重与糖尿病候选药物amycretin在最新研究中展现显著疗效，不 仅有效降低患者血糖，还实现明显体重下降，为这家在减重市场竞争中承压的药企带来一线利好。 研究显示，患者每周注射一次amycretin，36周内体重平均下降幅度高达14.5%；若以口服方式、每日一 次服用，患者体重也平均下降10.1%。诺和诺德表示，这是该公司在下一代代谢类药物布局中的关键成 果。 ...

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.The update marks the first evaluation of amycretin in people with type 2 diabetes.Novo Nordisk is planning to initiate a phase 3 development program with amycretin for adults with type 2 diabetes in 2026. In June, the company said it planned to initiate a phase 3 development for amycretin for adults with overweight or obesity in the first quarter of 2026.The trial evaluated once-weekly su ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions. ...

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study. ...